Therapeutic strategies for reversing cardiac fibrosis in hearts supported by ventricular assist devices

Document Type

Article

Publication Date

12-1-2025

Publication Title

Drug discovery today

Keywords

Humans, Heart-Assist Devices, Fibrosis, Animals, Heart Failure, Myocardium

Abstract

Left ventricular assist devices (LVADs) support patients with end-stage heart failure, yet myocardial recovery and device explant remains rare because of persistent cardiac fibrosis. This review examines the integration of molecular mechanisms and highlights therapeutic targets emerging from clinical and preclinical studies, with a focus on mechanisms that differentiate responders from non-responders. Key pathways include extracellular matrix remodeling, fibroblast activation, cellular plasticity, endothelial-to-mesenchymal transition, immune modulation, and post-transcriptional regulation via alternative polyadenylation. Advancing these mechanistic insights could enable biomarker-driven strategies to overcome the current barriers to improving recovery rates in patients supported by LVADs.

Medical Subject Headings

Humans; Heart-Assist Devices; Fibrosis; Animals; Heart Failure; Myocardium

PubMed ID

41265516

Volume

30

Issue

12

First Page

104547

Last Page

104547

Share

COinS